幽门螺杆菌治疗对老年人胃癌发病率的影响
该研究基于香港医院管理局数据库,纳入2003年1月至2012年12月接受含克拉霉素根除治疗的73,237例幽门螺杆菌感染者,随访中位7.6年,比较其胃癌发病率与年龄性别匹配的普通人群预期发病率。结果显示60岁及以上接受治疗者胃癌风险显著低于普通人群(SIR 0.82,95%CI 0.69-0.97,P=0.02),40-59岁和60岁及以上组在根除10年及以上后风险显著降低。
要点
- 60岁及以上幽门螺杆菌治疗者胃癌风险低于匹配普通人群(SIR 0.82,95%CI 0.69-0.97,P=0.02)。
- 40-59岁组根除10年及以上后胃癌风险显著降低(SIR 0.32,95%CI 0.08-0.88,P=0.04)。
- 60岁及以上组根除10年及以上后胃癌风险显著降低(SIR 0.42,95%CI 0.42-0.84,P=0.02)。
核心结论
- 在香港公立医院数据库分析中,幽门螺杆菌治疗与胃癌风险降低相关,尤其在老年人及治疗10年及以上后。
研究设计与样本
- 基于香港医院管理局数据库的队列研究,纳入2003年1月至2012年12月接受含克拉霉素根除治疗的73,237例幽门螺杆菌感染者,并与2003年至2014年香港癌症登记处年龄性别匹配的普通人群预期发病率比较。
主要发现
- 73,237例接受根除治疗者中,中位随访7.6年期间200例(0.27%)发生胃癌。
- 60岁及以上治疗者胃癌风险显著低于匹配普通人群(SIR 0.82,95%CI 0.69-0.97,P=0.02),年轻组无显著差异。
- 根除10年及以上后,40-59岁组胃癌风险显著低于普通人群(SIR 0.32,95%CI 0.08-0.88,P=0.04)。
- 根除10年及以上后,60岁及以上组胃癌风险显著低于普通人群(SIR 0.42,95%CI 0.42-0.84,P=0.02)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Although eradication of Helicobacter pylori infection reduces the risk of gastric cancer, few data are available on its effects in older subjects. We compared the age-specific risk of gastric cancer in a large cohort of subjects who received H pylori eradication therapy vs a matched general population. METHODS: We searched the Hospital Authority database of Hong Kong to identify individuals with H pylori infection who had received a course of clarithromycin-containing eradication therapy from January 2003 through December 2012. We compared the gastric cancer incidence in this cohort with the expected incidence for the local general population by retrieving the gastric cancer incidence of the age- and sex-matched population from 2003 through 2014 (the latest available year) from the Hong Kong Cancer Registry. The primary outcome was the incidence of gastric cancer development in the cohort treated for H pylori infection vs the expected number of gastric cancer cases in the general population. Analyses were conducted by a priori age groups of less than 40 years, 40-59 years, and 60 years or older. RESULTS: Among 73,237 subjects infected with H pylori who received eradication therapy, 200 (0.27%) developed gastric cancer during a median follow-up time of 7.6 years. Compared with the matched general population, the gastric cancer risk was significantly lower in subjects 60 years or older who had received H pylori treatment (standardized incidence ratio [SIR], 0.82; 95% confidence interval [CI], 0.69-0.97; P = .02) but not in younger groups. When data were stratified based on time from H pylori treatment (less than 5 years, 5-9 years, and 10 or more years), the risk of gastric cancer was significantly lower than the general population 10 or more years after eradication in the group 40-59 years old (SIR 0.32; 95% CI, 0.08-0.88; P = .04) and the group 60 years or older (SIR, 0.42; 95% CI, 0.42-0.84; P = .02) than the other age groups. CONCLUSIONS: In an analysis of data from a public hospital database on Hong Kong, we associated treatment of H pylori infection with a lower risk of gastric cancer, particularly in older subjects, 10 or more years after treatment.
引用
- Leung WK, Wong IOL, Cheung KS, et al. Effects of Helicobacter pylori Treatment on Incidence of Gastric Cancer in Older Individuals. Gastroenterology. 2018. PMID: 29550592. doi:10.1053/j.gastro.2018.03.028
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。